Protocol group

medication-lipid

6 protocols · 31 outcomes with evidence

Subgroups

Protocols (6)

Outcomes & scoring

biomarker-creatine-kinase-mb-isoenzyme-serum-peak-post-marathon-24-hours-change-from-baseline-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-statin-marathon-training-concurrent	-25	55	37

biomarker-creatine-kinase-serum-total-24-hours-post-marathon-change-from-baseline-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-statin-marathon-training-concurrent	-30	55	37

biomarker-lipid-apolipoprotein-b-serum-milligrams-per-deciliter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-evolocumab-bempedoic-acid-combined	+80	45	1

biomarker-lipid-hdl-cholesterol-serum-milligrams-per-deciliter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+65	45	1

biomarker-lipid-ldl-cholesterol-serum-milligrams-per-deciliter-measured2 evidence rows

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+95	50	1
medication-lipid-lowering-evolocumab-bempedoic-acid-combined	+80	45	1

biomarker-lipid-ldl-cholesterol-serum-millimoles-per-liter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+80	45	1

biomarker-lipid-total-cholesterol-serum-milligrams-per-deciliter-measured2 evidence rows

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+75	50	1
medication-lipid-lowering-alirocumab-ezetimibe-combined	+70	50	1

biomarker-lipid-total-cholesterol-serum-millimoles-per-liter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+75	45	1

biomarker-lipid-triglycerides-serum-fasting-milligrams-per-deciliter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-atorvastatin-daily-generic	+15	15	1

biomarker-liver-aminotransferases-sum-serum-units-per-liter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+30	40	1

biomarker-myoglobin-serum-post-marathon-change-from-baseline-nanograms-per-milliliter-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-statin-marathon-training-concurrent	0	55	37

cognition-clarity-improvement-perceived-rating-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+55	45	1

gastrointestinal-diarrhea-episodes-per-day-count-self-reported-measured1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-30	30	1

gastrointestinal-gastroesophageal-reflux-severity-nrs-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-60	45	1

immune-allergy-reaction-occurrence-detected-binary-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-single-dose-initial	-90	75	1

mood-depression-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-65	45	1

pain-intensity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-20	30	1

pain-muscle-cramps-frequency-episodes-per-week-count-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-45	35	1

pain-musculoskeletal-ache-numbness-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-50	35	1

pain-musculoskeletal-joint-muscle-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-70	45	1

pain-musculoskeletal-joint-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-55	40	1

pain-musculoskeletal-stiffness-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-60	40	1

pain-numbness-peripheral-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-60	40	1

respiratory-dyspnea-severity-nrs-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-40	35	1

skin-hair-loss-severity-nrs-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-65	40	1

skin-nasal-lesion-count-number-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-45	35	1

symptom-edema-lower-extremity-severity-nrs-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-ezetimibe-combined	-40	35	1

vestibular-dizziness-severity-nrs-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-55	35	1

vitality-fatigue-severity-numeric-rating-scale-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-25	30	1

vitality-stamina-increase-rating-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	+45	35	1

vitals-cardiac-palpitations-occurrence-detected-binary-self-reported1 evidence row

Protocol	Effect	Confidence	N
medication-lipid-lowering-alirocumab-biweekly	-55	40	1

Path: medication › lipid